Literature DB >> 11377683

Mastocytosis: molecular mechanisms and clinical disease heterogeneity.

D D Metcalfe1, C Akin.   

Abstract

Systemic mastocytosis has one unifying feature: an unexplained and pathologic increase in mast cells in specific tissues. This observation, along with clinical disease heterogeneity has long suggested that mastocytosis is a disease of complex etiology. At the same time, the last decade has witnessed significant progress in identifying the critical elements that regulate mast cell growth and development. Human mast cells are now known to arise from CD34(+) progenitors, particularly under the influence of stem cell factor (SCF). This information in turn led to the critical observation that a substantial number of patients with mastocytosis exhibit activating mutations in c-kit, the receptor for SCF. And while this observation may well be key in understanding mastocytosis, this mutation alone does not explain all heterogeneity. It now appears that other influences such as genetic polymorphisms within the host may influence the course of disease in those with KIT mutations; and that the search for additional molecular events capable of creating disease diversity must continue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377683     DOI: 10.1016/s0145-2126(01)00046-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

Review 1.  Mastocytosis and disorders of mast cell proliferation.

Authors:  Joanne K Simpson; Dean D Metcalfe
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

Authors:  Noria Harir; Cédric Boudot; Katrin Friedbichler; Karoline Sonneck; Rudin Kondo; Séverine Martin-Lannerée; Lukas Kenner; Marc Kerenyi; Saliha Yahiaoui; Valérie Gouilleux-Gruart; Jean Gondry; Laurence Bénit; Isabelle Dusanter-Fourt; Kaïss Lassoued; Peter Valent; Richard Moriggl; Fabrice Gouilleux
Journal:  Blood       Date:  2008-06-25       Impact factor: 22.113

3.  Origin of stem cells in the BM niche: new clues from mastocytosis.

Authors:  Krisztian Nemeth; Eva Mezey
Journal:  Blood       Date:  2016-02-11       Impact factor: 22.113

4.  Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.

Authors:  Christopher L Corless; Patina Harrell; Mario Lacouture; Troy Bainbridge; Claudia Le; Ken Gatter; Clifton White; Scott Granter; Michael C Heinrich
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

5.  Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis.

Authors:  M Laroche; J Bret; A Brouchet; B Mazières
Journal:  Clin Rheumatol       Date:  2006-08-11       Impact factor: 2.980

Review 6.  Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice.

Authors:  Polliana Mihaela Leru
Journal:  Cureus       Date:  2022-02-13

7.  Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis.

Authors:  Karin Hartmann; Metin Artuc; Stephan E Baldus; Thomas K Zirbes; Barbara Hermes; Juergen Thiele; Yoseph A Mekori; Beate M Henz
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Clinical correlates of blood serotonin levels in patients with mastocytosis.

Authors:  N M Kushnir-Sukhov; E Brittain; L Scott; D D Metcalfe
Journal:  Eur J Clin Invest       Date:  2008-12       Impact factor: 4.686

Review 9.  Mast Cell-Biomaterial Interactions and Tissue Repair.

Authors:  Emily W Ozpinar; Ariana L Frey; Glenn Cruse; Donald O Freytes
Journal:  Tissue Eng Part B Rev       Date:  2021-01-21       Impact factor: 6.389

10.  Mastocytosis in children and adults: clinical disease heterogeneity.

Authors:  Magdalena Lange; Bogusław Nedoszytko; Aleksandra Górska; Anton Zawrocki; Michał Sobjanek; Dariusz Kozlowski
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.